


## PATENTS

Attorney Docket No. 25846-0003  
FORMAL COMMUNICATION

## CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being transmitted by facsimile to the US PTO at fax  
number 703-872-9306 on October 10, 2002.  
Derek P. Freyberg, Reg. No. 29,25010/10/02  
Date

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Elfi Beidermann et al.

Confirmation No.: 7777

App. No.: 09/693,558

Art Unit: 1614

Filed: October 20, 2000

Examiner: Phyllis G. Spivack

For: Use of vitamin PP compounds


Commissioner for Patents  
Washington, D.C. 20231

Sir:

## TRANSMITTAL

Transmitted herewith for filing in the above-entitled patent application are the following:  
Response to Office Action, and Information Disclosure Statement (with 1 document)Please charge the fee of \$18 for one additional claim over 20; and any additional fees that  
may be required, to Deposit Account No. 08-1641, referring to 25846-0003.

Respectfully submitted,

  
Derek P. Freyberg  
Attorney for Applicants  
Reg. No. 29,250Customer No. 25213  
Heller Ehrman White & McAuliffe LLP  
275 Middlefield Road  
Menlo Park CA 94025-3506  
(650) 324-7014  
October 10, 2002

PATENTS  
Attorney Docket No. 25846-0003  
FORMAL COMMUNICATION

## CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being transmitted by facsimile to the US PTO at fax number 703-872-9306 on October 10, 2002.

Derek P. Freyberg  
Derek P. Freyberg, Reg. No. 29,250

10/10/02  
Date

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Elfi Beidermann et al.

: Confirmation No.: 7777

App. No.: 09/693,558

: Art Unit: 1614

Filed: October 20, 2000

: Examiner: Phyllis G. Spivack

For: Use of vitamin PP compounds

Commissioner for Patents  
Washington, D.C. 20231

01/06/2003 TSUGGS 00000004 081641 09693558

01 FC:1202 Sir: 18.00 CH

## RESPONSE TO OFFICE ACTION

In response to the Office Action mailed July 12, 2002, and in accordance with the telephone interview between Examiner Spivack and Applicants' attorney in early September, please enter the following amendment and consider the following remarks.

## AMENDMENT

In the Claims:

Amend claims 37, 39, 40, 41 - 46, 48, and 49 to read as follows:

37.(Amended) The method of claim 32 where the compound having vitamin PP activity or a prodrug thereof is tryptophan.

39.(Amended) The method of claim 50 where the cancerostatic or immunosuppressive agent is selected from the group consisting of

N-[2-(1-benzylpiperidin-4-yl)ethyl]-3-(pyridin-3-yl)propionamide;

N-[2-[1-(2-phenylethyl)piperidin-4-yl]ethyl]-3-(pyridin-3-yl)-propionamide;